Effectiveness and costs of post-diagnosis treatment in dementia coordinated by multidisciplinary memory clinics in comparison to treatment coordinated by general practitioners.

Completed

• Conditions: Alzheimer's disease; Dementia; 10012272

• Registration Number: NL-OMON30964
• Lead Sponsor: niversitair Medisch Centrum Sint Radboud

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 228

Inclusion Criteria

1.The patients fulfil DSM-IV TR criteria for dementia with a Clinical Dementia Rating of 1 or 2 (CDR, Hughes, 1982), and MiniMental State Examination (MMSE) score between 10 and 26.
2. All patients are diagnosed as having dementia in one of the participating 7 MMCs.
3. Each patient has a caregiver who is in touch with the patient at least once a week.
4. Patients and carers gave informed consent for participation in the study.
5. All patients are living independently at the start of the study (not in a nursing home, but they may reside in or next to a home for the aged).
6. Each patient has a specific target for post-diagnosis care as formulated by the MMCs (for example: drug treatment with cholinesterase inhibitors in probabale AD; or specific co-morbidity such as paranaoid delusions which asks for drug treatment, care-coordination and/or psychosocial treatment)

Exclusion Criteria

Exclusion criteria
1. Severe behavioural disturbances, such as severe depression and aggression to such an extend that participation in this trial is impossible (as judged by the responsible MMC-specialist).
2. Physical co-morbidity requiring a clear priority for another more somatically oriented therapy.
3. Lack of care/support, which probably will cause insufficient compliance to the intervention and the research protocol.
4. Severe problems in vision and/or hearing that make the collection of research data impossible.
5. Uncomplicated dementia patients, with no wish for symptomatic drug treatment, in whom MMcs have no specific advices or treatment targets, except for the diagnostic disclosure.
6. Expression of unwillingness to participation.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>PRIMARY OUTCOME MEASURES: Patients: Health-related quality of life as measured<br /><br>with a dementia specific HrQoL-instrument (i.e. QoL-AD) and functional<br /><br>performance in daily living as measured by the IDDD (Instrumental activities of<br /><br>Daily living in Dementia Diagnosis); Informal caregivers: caregiver burden as<br /><br>measured with the Sense of Competence Questionnaire (SoCQ).<br /><br><br /><br>Costs will be assessed from a societal perspective, using the Resource<br /><br>Utilization in Dementia-questionnaire (RUD), which has been used in several<br /><br>other economic evaluations in AD treatment.<br /><br><br /><br>See page 14-15 from the protocol for a detailed description</p><br>